6533b85dfe1ef96bd12be770
RESEARCH PRODUCT
Characteristics of SARS-CoV-2 variants of concern B.1.1.7, B.1.351 or P.1: data from seven EU/EEA countries, weeks 38/2020 to 10/2021
Funk T.Pharris A.Spiteri G.Bundle N.Melidou A.Carr M.Gonzalez G.Garcia-leon A.Crispie F.O'connor L.Murphy N.Mossong J.Vergison A.Wienecke-baldacchino A. K.Abdelrahman T.Riccardo F.Stefanelli P.Di Martino A.Bella A.Lo Presti A.Casaca P.Moreno J.Borges V.Isidro J.Ferreira R.Gomes J. P.Dotsenko L.Suija H.Epstein J.Sadikova O.Sepp H.Ikonen N.Savolainen-kopra C.Blomqvist S.Mottonen T.Helve O.Gomes-dias J.Adlhoch C.Macori G.Russell L.Yandle Z.Bennett C.O'byrne E.Murphy A.Tuite G.Conroy A.Duffy M.Morley U.Keoghan B.Ford I.Kennedy M.Mcdonnell S.Flynn A.Clarke A.Crowley A.Martin C.Kelly E.Foxton J.Hare D.Dunford L.Connell J.Moran J.Dean J.Fanning S.Rajan L.De Gascun C.Kenny J.Cotter P.Walsh C.Lawton E.Fitzpatrick A.Mullins E.Della Bartola M.Mccabe M.Stapleton P.Meaney C.Fanning L.Prentice M.Macsharry J.Dempsey C.Mallon P.Leon A.Chaturvedi A.Coughlan S.Mcandrew G.Reddington K.Walsh F.Fitzpatrick D.Smyth C.O'dwyer T.Chambers T.Clarke L.Jebb D.Klopp J.Kavanagh D.Haslam K.Buckley P.Lemass K.Fitzpatrick F.Burns K.Cafferkey J.Richmond A.Foley M.Sanchez-morgado J.Chalapati S.Pinnamaneni N.Crosbie C.Limbachiya D.Tinago W.Garcia Leon A. A.Miles S.Alalwan D.Negi R.Macken A.Feeney E.Kenny G.Mccann K.Kelly N.Blair M.Mccann R.Kenny C.O'brion C.Waqas S.Savinelli S.Doran P.Bracken T.Varghese P.Lambert J. S.Cotter A.Muldoon E.Sheehan G.Mcginty T.Lambert J.Green S.Leamy K.De Barra E.Mcconkey S.Kelly C.Horgan M.Sadlier C.Yousif O.O'donnell J.Fitzgerald M.Petty-saphon N.Cuddihy J.Fiore S.Fabiani C.Benedetti E.Di Mario G.Facchini M.Puzelli S.Calzoletti L.Fontana S.Venturi G.Fortuna C.Marsili G.Amendola A.Stuppia L.Savini G.Picerno A.Lopizzo T.Dell'edera D.Minchella P.Greco F.Mauro M. V.Viglietto G.Atripaldi L.Limone A.D'agaro P.Licastro D.Marcello A.Capobianchi M. R.Icardi G.Bruzzone B.Lillo F.Orsi A.Pariani E.Baldanti F.Gismondo M. R.Maggi F.Caruso A.Ceriotti F.Boniotti B.Bagnarelli P.Garofalo S.Scutella M.Pagani E.Collini L.Ghisetti V.Ru G.Chironna M.Parisi A.Rubino S.Serra C.Piras G.Coghe F.Vitale F.Tramuto F.Scalia G.Palermo C. I.Mancuso G.Di Gaudio F.Vullo S.Reale S.Cusi M. G.Rossolini G. M.Pistello M.Mencacci A.Camilloni B.Severini S.Di Benedetto M.Calogero T.Monne I.Biscaro V.Covid Study Groupssubject
Infecções Respiratórias2019-20 coronavirus outbreakmedicine.medical_specialtyCoronavirus disease 2019 (COVID-19)Critical CareEpidemiologySevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)variants of concernSettore MED/42 - Igiene Generale E Applicata03 medical and health sciences0302 clinical medicineVirologyInternal medicineMedicineHumansIntensive care admission030212 general & internal medicineCOVID-19; Europe; SARS-CoV-2; surveillance; variants of concern; Critical Care; Europe; Humans; COVID-19; SARS-CoV-2Surveillancebusiness.industrySARS-CoV-2030503 health policy & servicesPublic Health Environmental and Occupational HealthCOVID-19Odds ratioConfidence intervalEuropesurveillanceVariants of ConcernCOVID-19 Europe SARS-CoV-2 surveillance variants of concern0305 other medical sciencebusinessRapid CommunicationHumandescription
COVID study groups - PORTUGAL: Portuguese Laboratory Network for the Diagnosis of COVID-19 and Public Health Department of the Health Administrative Regions, Physicians that provided data and samples from suspected cases and SARS-CoV-2 genetic characterization. INSA laboratory team for the diagnosis of SARS-CoV-2. Algarve Biomedical Center and Unilabs. We compared 19,207 cases of SARS-CoV-2 variant B.1.1.7/S gene target failure (SGTF), 436 B.1.351 and 352 P.1 to non-variant cases reported by seven European countries. COVID-19 cases with these variants had significantly higher adjusted odds ratios for hospitalisation (B.1.1.7/SGTF: 1.7, 95% confidence interval (CI): 1.0-2.9; B.1.351: 3.6, 95% CI: 2.1-6.2; P.1: 2.6, 95% CI: 1.4-4.8) and B.1.1.7/SGTF and P.1 cases also for intensive care admission (B.1.1.7/SGTF: 2.3, 95% CI: 1.4-3.5; P.1: 2.2, 95% CI: 1.7-2.8). ECDC internal funds. The ICSC and the AIID Cohort are supported by Science Foundation Ireland under the Science Foundation Ireland, Enterprise Ireland, IDA Ireland COVID-19 Rapid Response Funding Call (Grant number: COVID-RRC 20/COV/0103 and COVID-RRC 20/COV/0305). info:eu-repo/semantics/publishedVersion
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2021-04-22 |